10,308 Shares in DexCom, Inc. (NASDAQ:DXCM) Bought by Erste Asset Management GmbH

Erste Asset Management GmbH purchased a new stake in DexCom, Inc. (NASDAQ:DXCM) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 10,308 shares of the medical device company’s stock, valued at approximately $694,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in DXCM. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of DexCom during the 2nd quarter valued at approximately $25,000. Sachetta LLC raised its position in shares of DexCom by 255.2% in the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after acquiring an additional 171 shares during the period. Riverview Trust Co boosted its stake in shares of DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after acquiring an additional 232 shares in the last quarter. DT Investment Partners LLC grew its position in shares of DexCom by 492.2% during the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock valued at $43,000 after acquiring an additional 315 shares during the period. Finally, RPg Family Wealth Advisory LLC purchased a new position in shares of DexCom in the 3rd quarter valued at about $57,000. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Stock Up 2.0 %

DXCM stock opened at $80.91 on Wednesday. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The firm has a market cap of $31.60 billion, a PE ratio of 48.45, a PEG ratio of 2.43 and a beta of 1.12. The firm’s 50 day moving average price is $71.83 and its 200-day moving average price is $86.83. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46.

Insiders Place Their Bets

In related news, EVP Sadie Stern sold 4,259 shares of the business’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the sale, the executive vice president now directly owns 71,192 shares in the company, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Jacob Steven Leach sold 746 shares of the stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. This trade represents a 0.28 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 5,431 shares of company stock valued at $399,319 over the last quarter. 0.30% of the stock is owned by insiders.

Analysts Set New Price Targets

Several brokerages have commented on DXCM. Wells Fargo & Company raised their price objective on DexCom from $80.00 to $90.00 and gave the company an “overweight” rating in a report on Friday, October 25th. Leerink Partners reduced their price objective on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Stifel Nicolaus upped their price target on shares of DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, August 23rd. Finally, Piper Sandler reiterated an “overweight” rating and set a $90.00 price objective on shares of DexCom in a research note on Monday, August 26th. Seven analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $104.59.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.